Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The Role of Aldosterone on Sympathetic Nerve Activity and Insulin Sensitivity
NCT02102243Phase 4Withdrawn
- Start
- Nov 2010
- Primary completion
- Dec 2025
- Countries
- 1
01
Overview
Phase 4, open-label trial in hypertension (HTN) and primary aldosteronism (PA) (2 arms). Primary endpoint: Increase in muscle sympathetic nerve activity during hyperinsulinemic euglycemic clamp at 1 day. Planned start Nov 2010; status: withdrawn.
02
Conditions
hypertension (HTN)primary aldosteronism (PA)
Beyond the preview
Go deeper on NCT02102243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02102243.